EIP logo

Copyright © 2007-2026 European Immunogenicity Platform

Location photo

15th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals

22nd — 24th April 2024

Lisbon, Portugal

Symposium sponsors

Program

Download the program as a PDF
 

Monday, April 22nd 2024

Workshop Day
09:00 Coming Together
Daniel Kramer, Sanofi
Immunogenicity Risk Assessment
09:15 Consolidated EIP Proposal for Immunogenicity Risk Assessment
Veerle Snoeck, Joanna Grudzinska Goebel on behalf of EIP
10:15 coffee Coffee Break
In-silico and in-vitro Assays as Part of the Immunogenicity Risk Assessment
10:45 Immunogenicity potential assessment at Novartis
Anette Karle, Novartis
11:15 Immunogenicity potential assessment at Pfizer
Sophie Tourdot, Pfizer
11:45 Design and Implementation of a Risk-Based Strategy for Reducing Immunogenicity Risk of Protein Therapeutics
Karen Heyninck, Sanofi
12:15 cutlery 77 Lunch
13:30 Bring Your own Problems (Breakout Sessions)
Daniel Kramer, Sanofi
Arno Kromminga, BioNTech
Sebastian Spindeldreher, Integrated Biologix
Sofie Pattijn, ImmunXperts
Sophie Tourdot, Pfizer
Veerle Snoeck, UCB
Tim Hickling, Roche
Lydia Michaut, Novartis
15:00 coffee Coffee Break
15:30 Continue “Bring Your own Problems (Breakout Sessions)”
16:30 Closing of the Workshop Day
17:00 – 18:30 Meeting of the EIP Working Groups
Members of EIP working groups
 

Tuesday, April 23rd 2024

09:00 Welcome and Introduction by the EIP Chairman
Daniel Kramer, Sanofi
09:15 Spotlight Presentations: MHC Class I and its Importance for the Immunogenicity of Novel Modalities
Morten Nielsen, Technical University of Denmark
Zuben Sauna, FDA
Session 2: Prediction of Immunogenicity
Chair: Sebastian Spindeldreher
10:15 EIP NCIRA Working Group Update
Sophie Tourdot, on behalf of EIP
10:30 Immunogenicity: It’s Personal
Annie de Groot, EpiVax
11:00 coffee Coffee Break
11:00 canvas Poster Presentation
Short Talks
(15 minutes each)
11:30 High-Sensitive MAPPS Analysis for High-Confident Immunogenicity Risk Assessment
Elise Pepermans, ImmuneSpec
11:45 Standardization of in-Vitro Assays — Update from the AAPS/HESI Collaboration
Sofie Pattyn, ImmunXperts
12:00 Immunogenicity of Therapeutic Antibodies: Role of Aggregation in T Lymphocyte Response
Marc Pallardy, INSERM
12:15 cutlery 77 Lunch Break
13:30 Expanding the MAPPs Assay to MHC-II-DR, -DP and DQ Receptors
Axel Ducret, Roche
14:00 Naive and Memory FVIII-Specific Regulatory and Conventional CD4 T Cells Share Common Epitopes in Healthy Individuals
Bernard Maillere, CEA
Session 3: Immunogenicity Assays
Chair: Veerle Snoeck
14:30 EIP Immunogenicity Assays Working Group Update
Marina Ichetovkin, on behalf of EIP
14:45 coffee Coffee Break
14:45 canvas Poster Presentation
15:15 Domain Characterization of Bi-specifics in the ADA and in the NAb Assay
Issa Jyamubandi, Resolian Bioanalytics
15:45 Case study: Developing an ADA assay with enhanced Free Drug Tolerance for Octreotide
René Wuttke, Debiopharm
16:15 Phase-Appropriate Implementation of a Domain Specificity Strategy
Matthias Reichel, BioAgilytix
16:45 The IVDR and its Impact on Clinical Immunogenicity Assay Development
Robert Nelson, BioAgilytix
Session 3: Social Event
Chair: Barbara Vercruyssen
18:00 toast Get Together
23:00 moon stars Good Night
 

Wednesday, April 24th 2024

Session 4: Immunogenicity of New Modalities
Chair: Arno Kromminga
09:00 Development of an ELISpot Assay for the Assessment of AAV Peptides to Examine Immune Safety
Alison Johnson, Boehringer Ingelheim
09:30 Immunogenicity Risk Assessment for mRNA/LNP Therapies
Joanna Grudzinska Goebel, Bayer
10:00 Total versus Neutralizing antibody assays against Adeno-associated virus, what is the best?
Vivek Nayak, UCB
10:30 Orthogonal Approach for AAV Immunogenicity Assessment: Evaluating Total and Neutralizing Antibodies
Michael Tovey, SVAR
11:00 coffee Coffee Break
11:00 canvas Poster Presentation
Session 5: Clinical Relevance of Immunogenicity
Chair: Lydia Michaut
11:30 Novel Approaches for Treatment of Autoimmunity: Application to Mitigate Immunogenicity of Biological Therapeutics?
Amy Rosenberg, EpiVax
12:00 ADA Monitoring Strategy for Repetitive High Doses of Biologics Therapies: Efficiently Integrating Scientific, Technical, and Regulatory Aspects
Manisha Saxena, Novartis
12:30 The Wonderful World of Immunogenicity; Scientific Understanding, Clinical Relevance, and Regulatory Necessity
Floris Loeff, Sanquin
13:00 cutlery 77 Lunch Break
Short Talks
(15 minutes each)
14:15 Drug T Cell Reactivity in Delayed Type Hypersensitivity – Evaluation with Cyto-LTT
Lester Thoo, ADR-AC
14:30 Evaluating Immediate Type Drug Allergy and Immunostimulation in Vitro with the Basophil Activation Test (BAT)
Daniel Yerly, ADR-AC
Session 6: Regulatory
Chair: Daniel Kramer
14:45 How CDER reviews Immunogenicity for Biologics- the Integrative Immunogenicity Assessment paradigm
Joao A. Pedras-Vasconcelos, FDA
15:30 New approaches to assess immunogenicity risk: Regulatory considerations
Daniela Verthelyi, FDA
16:00 Conference Summary & Outlook by the EIP Chairman
Daniel Kramer, Sanofi
16:15 Close of the conference
NOTE: If no download icon is shown against a session the speaker has not given permission for their slides to be published.

Downloads

Posters

Celerion
Low Cut Points: Where Has Our Biological Variability Gone?
KCAS Bio
Monitoring immunogenicity of your candidate vaccine by ELISpot: How to reduce assay variability?
Merck
Generic ADA Assay: a universal approach to enhance early phase and preclinical immunogenicity testing
Novartis
In Silico Immunogenicity Profiling Based On Drug / Pathogen Analogy
EIP-PCS
The EIP-Particle Characterisation Subcommittee
PEPperPRINT
A Chip-based Immunogenicity Risk Assessment Tool for Therapeutic Protein Products
Sanquin
Cross-reactivity of anti-drug antibodies against anti-CD20 therapeutic monoclonal antibodies with other anti-CD20 antibodies
Back to top